🇺🇸 FDA
Patent

US 12310929

Use of rasagiline for the treatment of restless legs syndrome

granted A61KA61K2300/00A61K31/135

Quick answer

US patent 12310929 (Use of rasagiline for the treatment of restless legs syndrome) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2300/00, A61K31/135, A61K31/16, A61K31/428